NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 248 filers reported holding NEKTAR THERAPEUTICS in Q4 2020. The put-call ratio across all filers is 0.43 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $13,469 | -48.9% | 22,599 | -50.7% | 0.00% | -100.0% |
| Q2 2023 | $26,338 | +90720.7% | 45,806 | +11.6% | 0.00% | 0.0% |
| Q1 2023 | $29 | +20.8% | 41,048 | +280.5% | 0.00% | 0.0% |
| Q4 2022 | $24 | -99.9% | 10,787 | -26.0% | 0.00% | 0.0% |
| Q3 2022 | $47,000 | +51.6% | 14,568 | +81.9% | 0.00% | 0.0% |
| Q2 2022 | $31,000 | +55.0% | 8,010 | +117.5% | 0.00% | – |
| Q1 2022 | $20,000 | -68.8% | 3,682 | -22.5% | 0.00% | -100.0% |
| Q4 2021 | $64,000 | -69.4% | 4,751 | -59.2% | 0.00% | -80.0% |
| Q3 2021 | $209,000 | +4.0% | 11,643 | -0.4% | 0.01% | 0.0% |
| Q2 2021 | $201,000 | +2.6% | 11,691 | +19.4% | 0.01% | +66.7% |
| Q1 2021 | $196,000 | -24.9% | 9,791 | -36.3% | 0.00% | -62.5% |
| Q4 2020 | $261,000 | +174.7% | 15,372 | +169.6% | 0.01% | +700.0% |
| Q3 2020 | $95,000 | -92.8% | 5,701 | -90.0% | 0.00% | -98.1% |
| Q2 2020 | $1,318,000 | +8137.5% | 56,894 | +6409.6% | 0.05% | +5300.0% |
| Q1 2020 | $16,000 | -92.0% | 874 | -90.5% | 0.00% | -94.1% |
| Q4 2019 | $199,000 | +25.9% | 9,204 | +6.1% | 0.02% | +54.5% |
| Q3 2019 | $158,000 | +1875.0% | 8,677 | +3992.9% | 0.01% | +1000.0% |
| Q2 2019 | $8,000 | -97.2% | 212 | -97.5% | 0.00% | -94.1% |
| Q1 2019 | $285,000 | +106.5% | 8,508 | +103.2% | 0.02% | +70.0% |
| Q4 2018 | $138,000 | +55.1% | 4,186 | +130.9% | 0.01% | +100.0% |
| Q2 2018 | $89,000 | -78.1% | 1,813 | -89.3% | 0.01% | -85.3% |
| Q3 2017 | $406,000 | +20200.0% | 16,919 | +16819.0% | 0.03% | – |
| Q1 2017 | $2,000 | -83.3% | 100 | -90.0% | 0.00% | -100.0% |
| Q4 2016 | $12,000 | 0.0% | 1,004 | +16.7% | 0.00% | -50.0% |
| Q1 2016 | $12,000 | -65.7% | 860 | -73.1% | 0.00% | -33.3% |
| Q3 2015 | $35,000 | +1650.0% | 3,198 | +2090.4% | 0.00% | – |
| Q2 2015 | $2,000 | -88.9% | 146 | -87.6% | 0.00% | -100.0% |
| Q4 2014 | $18,000 | -90.5% | 1,174 | -92.5% | 0.00% | -90.5% |
| Q3 2014 | $189,000 | +293.8% | 15,639 | +292.2% | 0.02% | +250.0% |
| Q1 2014 | $48,000 | +4.3% | 3,988 | -2.2% | 0.01% | -25.0% |
| Q4 2013 | $46,000 | -57.4% | 4,078 | -60.4% | 0.01% | -33.3% |
| Q3 2013 | $108,000 | – | 10,295 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |